| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- Ilginatinib
-
- $58.00
-
2026-07-27
- CAS:1239358-86-1
- Purity: 98.40%
- Supply Ability: 10g
- Ilginatinib
-
- $58.00
-
2026-07-27
- CAS:1239358-86-1
- Purity: 98.40%
- Supply Ability: 10g
|
| Product Name: | NS-018 | | Synonyms: | N2-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine;NS018;ILGINATINIB;ILGINATINIB (NS-018);NS-018;2,6-Pyridinediamine, N2-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-;JAK3,Janus kinase,Inhibitor,NS 018,JAK,JAK2,orally,Tyk2,NS018,Ilginatinib,inhibit,JAK1,bioavailable;Ilginatinib, 10 mM in DMSO;Ilginatinib | | CAS: | 1239358-86-1 | | MF: | C21H20FN7 | | MW: | 389.43 | | EINECS: | | | Product Categories: | | | Mol File: | 1239358-86-1.mol |  |
| | NS-018 Chemical Properties |
| Boiling point | 574.1±50.0 °C(Predicted) | | density | 1.31±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 34 mg/mL (87.31 mM) | | form | Solid | | pka | 2.43±0.10(Predicted) | | color | Light yellow to yellow |
| | NS-018 Usage And Synthesis |
| Uses | Ilginatinib (NS-018) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). | | in vivo | Ilginatinib (NS-018) (12.5, 25, 50, 100 mg/kg, p.o.) potently prolongs the survival of mice and reduces splenomegaly in a mouse Ba/F3-JAK2V617F disease model[1].
Ilginatinib (NS-018) (25, 50 mg/kg, p.o.) significantly reduces leukocytosis, hepatosplenomegaly and extramedullary hematopoiesis, improves nutritional status, and prolongs survival in JAK2V617F transgenic mice | | IC 50 | JAK2: 0.72 nM (IC50); Tyk2: 22 nM (IC50); JAK1: 33 nM (IC50); JAK3: 39 nM (IC50) | | References | [1] Nakaya Y, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J. 2011 Jul;1(7):e29. DOI:10.1038/bcj.2011.29
[2] Kuroda J, et al. NS-018, a selective JAK2 inhibitor, preferentially inhibits CFU-GM colony formation by bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients. Leuk Res. 2014 May;38(5):619-24. DOI:10.1016/j.leukres.2014.03.001 |
| | NS-018 Preparation Products And Raw materials |
|